Favezelimab (MK-4280)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Favezelimab (MK-4280), covering 2025-05-30 to 2025-05-30. Get the full timeline:
Most recent: Clinical Trial Update: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) [Phase 1]